
APLT DEADLINE ALERT: Kirby McInerney LLP Alerts Applied Therapeutics, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit
The law firm of Kirby McInerney LLP alerts investors of the imminent February 18, 2025 deadline, to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Applied Therapeutics, Inc. ('Applied Therapeutics' or the 'Company') (NASDAQ:APLT) securities between January 3, 2024, to December 2, 2024 ('the Class Period'). The firm encourages investors to contact the firm as soon as possible to be appointed lead plaintiff.
[LEARN MORE ABOUT THE CLASS ACTION]
On November 27, 2024, Applied Therapeutics issued a press release announcing that it had received a Complete Response Letter ('CRL') for the New Drug Application ('NDA') for govorestat, the Company's lead product candidate. The CRL indicated that the FDA had completed its review of the application and determined that it was unable to approve the NDA in its current form citing deficiencies in the clinical application. On this news, the price of Applied Therapeutics shares declined by $6.54 per share, or approximately 76%, from $8.57 per share on November 27, 2024, to close at $2.03 per share on December 2, 2024.
Then, on December 2, 2024, after market hours, Applied Therapeutics disclosed that it had received a 'warning letter' from the FDA referring to the clinical trial issues underlying the CRL. According to the Company's description of the warning letter, the FDA stated in pertinent part that: 'The letter identified issues related to electronic data capture, which the Company believes were addressed in prior communications with the agency, including by providing detailed paper and video records. The letter also refers to a dosing error in the dose escalation phase of the study resulting in slightly lower levels that targeted in a limited number of patients, which were remedied prior to achieving maintenance dosing identified issues related to electronic data capture and a dosing error in the dose-escalation phase of the study, resulting in slightly lower levels than targeted in a limited number of patients. On this news, the price of Applied Therapeutics shares declined by $0.49 per share, or more than 25%, over 3 consecutive days, from $1.75 per share on December 2, 2024, to $1.69 on December 3, 2024, $1.38 on December 4, 2024, and finally, to close at $1.29 on December 5, 2024.
The lawsuit alleges that Defendants, throughout the Class Period, misled investors by providing positive statements to investors, while at the same time concealing material adverse facts concerning the true state of Applied Therapeutic's trials; notably, electronic data capture issues and a dosing error in the dose-escalation phase of the study.
If you purchased or otherwise acquired Applied Therapeutics securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Thomas W. Elrod, Esq.
212-699-1180
SOURCE: Kirby McInerney LLP
Copyright Business Wire 2025.
PUB: 02/04/2025 08:00 PM/DISC: 02/04/2025 08:01 PM
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Jim Cramer Highlights That Dollar Tree (DLTR) Has 'More Trouble With the Tariffs'
We recently published a list of . In this article, we are going to take a look at where Dollar Tree, Inc. (NASDAQ:DLTR) stands against other stocks that Jim Cramer discusses. Discussing the impact of tariffs on Dollar Tree, Inc. (NASDAQ:DLTR), Cramer stated: 'Discount retailers tend to do better when the consumers' feeling stretched thin, and you know the consumer's feeling that way. But Dollar General and Dollar Tree have behaved very differently after reporting earnings over the past couple days… Then today, Dollar Tree reported what I also thought was a pretty good quarter, but its stock got eviscerated, down 8%. What explains the disparity here?… The difference between these two comes down to what they had to say about their ability to control costs and offset the impact of, you bet, go ahead, the president's tariffs… A shopper browsing through a discount retailers merchandise aisle filled with a wide variety of items. Dollar Tree (NASDAQ:DLTR) runs discount retail stores that carry a wide variety of products. The selection includes consumables, home essentials, seasonal items, apparel, and electronics. Overall, DLTR ranks 8th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of DLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Was Jim Cramer Right About Meta Platforms, Inc. (META)?
We recently published a list of . In this article, we are going to take a look at where Meta Platforms, Inc. (NASDAQ:META) stands against other stocks that Jim Cramer discusses. A viewer asked if Meta Platforms, Inc. (NASDAQ:META) still had technological upside, particularly under CEO Mark Zuckerberg's leadership. In that older segment, Cramer expressed strong long-term optimism, suggesting Meta was investing in something bigger than the public could yet see. He responded with: 'I think there is. I mean, I think that they're going to be in competition in something we don't know yet. They're buying too many of the Nvidia cards for me to think they're just going to continue to be just Instagram and Facebook and WhatsApp. I think there's much more in store for us and I think you got to stay long that stock. It is not an expensive stock.' Cramer was right to call it an inexpensive stock. It's now up +39.66% since those comments. Meta Platforms, Inc. (NASDAQ:META) is a technology company that owns Facebook, Instagram, and WhatsApp, and is investing heavily in AI and virtual reality platforms like the Metaverse. When asked about the stock again recently, Cramer gave his blessing to buy it, saying: 'I like your thinking very much. I think Meta's having a great quarter. I also think that they are without a doubt the best advertising bet. What happens if he actually starts, Mark Zuckerberg starts to want to, let's say, monetize WhatsApp? Do you know how much that darn thing's worth? I think you got horse sense. Good level to buy.' A team of developers working in unison to create the company's messaging application. Overall, META ranks 6th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18 minutes ago
- Yahoo
Informa TechTarget Announces Partnership with Outreach to Help Companies Build and Accelerate Sales Pipeline Through More Intelligent Prospecting
This powerful combination helps mutual customers drive better business outcomes by efficiently identifying and effectively engaging prospects in an active buying journey NEWTON, Mass., June 09, 2025--(BUSINESS WIRE)--TechTarget, Inc. ("Informa TechTarget") (Nasdaq: TTGT), global growth accelerator and leading provider of intent data and insights to the B2B technology sector, today announced a strategic partnership and integration with Outreach, the only workflow-first sales execution platform. The integration empowers mutual customers to connect the dots between active buyer research and sales engagement so they can book more meetings, drive better conversations, create more pipeline, and accelerate deal velocity. "Roughly 9 out of 10 initial conversations with BDRs never progress through the sales cycle. Our new integration addresses this challenge head-on by fueling the timely and relevant engagement required to maximize conversion and pipeline impact," said Jillian Coffin, Senior Vice President of Customer Enablement and Strategy, Informa TechTarget. "By automatically adding Informa TechTarget's Active Prospects directly into topically aligned Outreach sequences, reps can dramatically improve their ability to connect with warm contacts when they're actively researching relevant topics and solutions." The new integration empowers sales teams to: Streamline workflows between Priority Engine, Informa TechTarget's proprietary purchase intent data platform, and Outreach to maximize sales efficiency Instantly add Active Prospects directly into relevant Outreach sequences with one click Automatically export Active Prospects to topically aligned Outreach sequences on a weekly basis Key benefits of this strategic partnership include: Increased efficiency and improved focus: Informa TechTarget's precise, person-level intent data helps reps more quickly identify and prioritize prospects with demonstrated solution interest so they can focus their efforts squarely on accounts and prospects showing active buying behavior. Timely engagement: Informa TechTarget continuously identifies new prospects from in-market accounts who are actively researching relevant topics across our network and delivers these permissioned buyers directly to Outreach. These automated workflows improve success by reducing the time to get from intent signal to outreach, enabling reps to engage prospects while they are actively researching and get into deals earlier. Improved conversion: Informa TechTarget delivers deep, real-time insights into the specific needs, pain points, and current topics of interest for each individual buyer who is actively researching on their topically relevant editorial communities. With this contextual intelligence at their fingertips, sellers can personalize every touchpoint based on a prospect's demonstrated interests and drive meaningful conversations that increase conversion to opportunity. The Informa TechTarget-Outreach integration is available now to current Priority Engine Sales subscribers at no additional cost. Customers must have both a Priority Engine Sales subscription and an Outreach license to utilize the integration. To learn more, click here. About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc d/b/a Informa TechTarget. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Garrett MannVice President of Corporate CommunicationsInforma Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data